Altria Faces Challenges in Moving Beyond Smoking

Aug.31.2022
Altria Faces Challenges in Moving Beyond Smoking
Altria faces challenges in diversifying beyond tobacco amidst FDA nicotine limits and the potential loss of Juul investments.

The Altria Group based in Henry County, United States, is promoting on its website that it is "going beyond smoking," despite the fact that its owner, Philip Morris USA, remains one of the world's largest producers of cigarettes and other tobacco products.


Currently, this company with 6,000 employees and a value of $26 billion may have to accelerate its efforts to phase out smoking faster than anticipated.


As part of President Biden's Cancer Moonshot plan, which aims to reduce cancer-related deaths in the United States by 50% over the next 25 years, the US Food and Drug Administration (FDA) has announced plans to restrict the nicotine content in cigarettes to "minimally or non-addictive" levels. The proposed rules are expected to be released in May 2023, with public feedback sought at that time. In addition, the FDA plans to ban the production of electronic cigarettes by Juul Labs Inc., which is 35% owned by Altria, headquartered in Washington, D.C. As of August, Juul's products remain on shelves despite FDA's decision in July to further review studies comparing e-cigarettes to traditional cigarettes, with no timeline for the process.


The potential for any future action to occur poses a challenge to Altria's long-term profitability and sustainability. In addition to federal government targets, Altria also faces other issues such as the US International Trade Commission's removal of Philip Morris' IQOS tobacco heating system from the US market in September 2021 due to patent disputes. Altria's $1.8 billion investment in Canadian cannabis company Cronos Group Inc. is unable to yield returns due to the lack of federal laws governing marijuana sales.


During a financial earnings call in late July, Billy Gifford, who was promoted from CFO to CEO of Altria in April 2020, acknowledged that it was a "critical point" for the tobacco industry in the United States. One month prior, The Wall Street Journal had referred to it as a "survival threat" particularly for large tobacco companies, including Altria.


During the release of their second quarter 2022 financial report in July, Altria reported a net income of $6.54 billion, a 5.7% decrease from the second quarter of 2021, closely in line with the company's projections for the year. Meanwhile, as of June 30th, Altria's $12.8 billion investment in e-cigarette company Juul, based in California, is under federal scrutiny (as well as facing numerous lawsuits) due to its appeal to underage tobacco users, causing its value to drop to $450 million.


According to Altria, if the e-cigarette manufacturer is banned from selling its e-cigarette products in the United States for one year or more, or if Altria holds no more than 10% of its initial investment, it may choose to terminate its non-compete agreement with Juul.


Altria has not yet sought to terminate its non-compete agreement because the company would also lose certain rights on the Juul board. "At this time, we still believe these investment rights are beneficial to us," said Altria spokesperson Jennifer Kelly via email. "Therefore, we currently do not have the option to waive our non-compete obligation, but we retain the right to do so in the future." Steve Marascia, an analyst at investment firm Capitol Securities Management in Richmond who holds stock in Altria, is keeping an eye on the company's progress and recommends a "buy" rating. He said the FDA's ban on Juul e-cigarettes and its mandate to lower nicotine levels would not pose a direct risk to Altria.


He said that Altria is still generating significant cash flow, allowing the company to continue paying dividends – a key area of interest for many investors who have witnessed Altria's consecutive 52-year dividend increases. "Dividends are crucial for stocks themselves, and maintaining the ability to pay dividends is also important for stocks.


However, ultimately, Altria will need to diversify away from cigarettes, noted Marascia. "Their options are either to seek out other products, make acquisitions, or possibly merge with another company.


At the beginning of the century, Altria was a more diversified company. Originally known as the Philip Morris Company, it changed its name in 2003 to the seemingly altruistic Altria Group, partly to distance itself from its tobacco business.


This follows years of negative news and lawsuits surrounding cancer deaths. In 1994, seven top American tobacco CEOs, including William Campbell of Philip Morris, testified before Congress that they did not believe nicotine was addictive. Four years later, Philip Morris and three other major tobacco manufacturers reached a settlement agreement, agreeing to settle state government lawsuits to recover tobacco-related health costs. Under the agreement, the four tobacco companies agreed to pay at least $206 billion to the 46 participating state governments, including Virginia, over 25 years.


In early 2007, Altria owned both Philip Morris USA and Philip Morris International, as well as an 88.1% stake in Kraft Foods. However, this did not last long. In March of 2007, Altria spun off the makers of Oreos and Oscar Mayer hot dogs as a separate stock, separating from Altria. In 1988, Altria acquired Kraft for $13.1 billion. Altria's investment in food began in 1985 when they acquired General Foods Corp., the manufacturer of products such as Tang beverages, Hostess snack cakes, and Maxwell House coffee.


However, Altria faced further legal challenges, including a federal lawsuit in 2006 brought against the company and co-defendants RJ Reynolds Tobacco Co. and Lorillard Tobacco Co. by Philip Morris USA, as well as a decline in tobacco sales. Despite this, Altria's efforts towards diversification continued over the following decade.


In 2008, as part of an ongoing restructuring process, Altria divested its overseas tobacco business, Philip Morris International, in order to separate PMI from the management of Altria's domestic cigarette business. At the same time, Altria relocated from its New York corporate headquarters to Henry County, where Philip Morris USA has established a base of operations.


The following year, Altria acquired UST Inc., the largest manufacturer of smokeless tobacco products such as snuff and chewing tobacco, as well as the Chateau Ste. Michelle wine brand. In 2021, Altria sold the brand to New York-based private equity firm Sycamore Partners for $1.2 billion in cash.


Currently, Altria's tobacco sales are primarily limited to the United States. In 2018, the company made two significant investments to strengthen its presence in the domestic marijuana and e-cigarette device markets. Altria has stated that it is committed to working with regulators and stakeholders to establish a regulated and legal marijuana market in the US, while the House and Senate are working on crafting unified policies.


Although Altria's $1.8 billion investment in Canadian company Cronos Group can be seen as a wise preparation for the future U.S. cannabis retail market, the tobacco manufacturer's $12.8 billion investment in Juul in 2018 is widely considered a massive mistake that quickly went south.


Statement:


This article is compiled from third-party information and is only intended for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the content. The translation of this article is only intended for industry communication and research purposes.


Due to limitations in the level of translation ability, the article translated may not express the same meaning as the original article. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any statements or positions regarding domestic, Hong Kong, Macau, Taiwan, or foreign affairs.


The copyright of compiled information belongs to the original media and the author. If there is any infringement, please contact us to remove it.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Swedish nicotine pouch brand Kelly White is building its strategy around adult female consumers. Founder and CEO Sophia Wilsby told 2Firsts that women accounted for around 70% of the brand’s repeat customers on HAYPP in Sweden in 2025. The interview explores female consumer segmentation, product and design differentiation, gender stereotypes, packaging regulation, and how independent brands can compete with global players such as ZYN and VELO while considering funding, partnerships and future ownership options.
Business
Sep.24
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
Acme Vape Ltd, the company behind UK vaping brand IVG, has received HM Revenue & Customs approval to operate an excise warehouse for vaping products and participate in the Vaping Duty Stamps Scheme. The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Acme Vape Ltd says its approved warehouse in Preston will become operational under the new regime on the same date.
Regulations
Sep.18 by 2Firsts Perspectives
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
EU Tobacco Tax Reform Targets November Push as Sweden Holds Nicotine-Pouch Minimum at €20 per Kilogram
EU Tobacco Tax Reform Targets November Push as Sweden Holds Nicotine-Pouch Minimum at €20 per Kilogram
The Irish presidency of the Council of the European Union is using bilateral talks to push the bloc’s Tobacco Taxation Directive toward a political agreement in November. According to Law360, citing an EU official, Sweden is unwilling to accept a minimum excise threshold above €20 per kilogram for nicotine pouches. Council negotiations have already lowered the European Commission’s original proposal, but a May 2026 presidency compromise still set the minimum at 10% of the tax-inclusive retail price or €30 per kilogram in 2028-29, with higher levels later.
Market
Sep.17 by 2Firsts Perspectives
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives